Eltrombopag/Eltrombopag vs Hetrombopag competition: Which one is better?

Eltrombopag and eltrombopag (Romiplostim) are medicines used to treat certain types of thrombocytopenia, specifically chronic immune thrombocytopenia (ITP) and other thrombocytopenias caused by problems with bone marrow production. Both drugs are drugs that promote platelet production, but there are certain differences in their mechanisms of action, administration methods, side effects, and efficacy. To help patients and clinicians make better decisions when choosing treatment options, this article will explore the differences between eltrombopag and heltrombopag in detail and analyze which one is more suitable for specific patients.

Eltrombopag (Eltrombopag) is an oral drug that is a non-peptide thrombopoietin (TPO) receptor agonist. It works by activating TPO receptors to stimulate platelet production in the bone marrow. Eltrombopag is initially used to treat chronic immune thrombocytopenia (ITP), where it increases platelet levels and reduces bleeding events. Eltrombopag is very convenient to administer. Patients only need to take it orally once a day, and the dosage can be adjusted according to the patient's specific condition.

In contrast, Romiplostim is a recombinant protein drug that is a TPO receptor agonist. It stimulates the bone marrow to produce more platelets by binding to the TPO receptor. Hetrombopag is an injectable drug that is given by subcutaneous injection, usually once a week. Although the efficacy of eltrombopag is similar to that of eltrombopag, because it is an injectable form, patient compliance may be affected, especially in the case of long-term treatment.

In terms of efficacy, both eltrombopag and heltrombopag have been proven to be effective in increasing platelet levels in ITP patients and reducing the risk of bleeding. According to clinical studies, there is little difference between the two in their effectiveness in increasing platelet counts. For example, a clinical trial showed that eltrombopag can significantly increase the platelet count of more than 70% of ITP patients within 12 weeks of treatment and continue to maintain it within the normal range. The therapeutic effect of Hetrombopag is equally excellent. Studies have shown that about 60% of patients can achieve clinically significant platelet increases through Hetrombopag treatment. However, although the efficacy of the two is similar, eltrombopag may have some advantages in terms of patient experience, especially for patients who are unwilling to take injections. The convenience of taking oral drugs is undoubtedly an important consideration.

In terms of side effects, the side effects of eltrombopag and heltrombopag are generally similar, and both may cause some minor side effects, such as headache, fatigue, nausea, etc. Common side effects of Eltrombopag also include abnormal liver function, anemia, dry mouth, etc. Some patients may need to regularly monitor liver function to avoid liver damage. The side effects of Hetrombopag are mainly injection site reactions, joint pain, etc. In addition, attention should be paid to the risk of excessive bone marrow hyperplasia during the use of Hetrombopag. Patients may develop problems such as abnormal bone marrow hyperplasia and need to be closely monitored.

Reference materials:https://go.drugbank.com/drugs/DB06210